Number of Shares and Voting Rights of Innate Pharma as of February 1, 2022
As of February 1, 2022, Innate Pharma SA reports a total of 79,543,377 ordinary shares outstanding. The company also has 6,514 preferred shares from 2016 and 7,581 preferred shares from 2017. The total theoretical voting rights amount to 80,301,217, while the exercisable voting rights stand at 80,282,642. This disclosure aligns with French regulations aimed at promoting transparency in share ownership and voting rights.
- Total number of shares outstanding stands at 79,543,377, indicating a stable share structure.
- Total number of theoretical voting rights is 80,301,217, enhancing shareholder participation.
- None.
Pursuant to the article L. 233-8 II of the French “Code de Commerce” and the article 223-16 of the French stock-market authorities (Autorité des Marchés Financiers, or “AMF”) General Regulation,
Total number of shares outstanding: |
79,543,377 ordinary shares |
|
|
6,514 Preferred Shares 2016 |
|
7,581 Preferred Shares 2017 |
||
Total number of theoretical voting rights (1): |
80,301,217 |
|
Total number of exercisable voting rights (2): |
80,282,642 |
(1) The total number of theoretical voting rights (or “gross” voting rights) is used as the basis for calculating the crossing of shareholding thresholds. In accordance with Article 223-11 of the AMF General Regulation, this number is calculated on the basis of all shares to which voting rights are attached, including shares whose voting rights have been suspended. The total number of theoretical voting rights includes voting rights attached to AGAP 2016 (2016 Preferred Shares), i.e. 130 voting rights for the AGAP 2016-1 and 111 voting rights for the AGAP 2016-2.
(2) The total number of exercisable voting rights (or “net” voting rights) is calculated without taking into account the shares held in treasury by the Company, with suspended voting rights. It is released so as to ensure that the market is adequately informed, in accordance with the recommendation made by the AMF on
About
Innate Pharma’s broad pipeline of antibodies includes several potentially first-in-class clinical and preclinical candidates in cancers with high unmet medical need.
Innate is a pioneer in the understanding of natural killer cell biology and has expanded its expertise in the tumor microenvironment and tumor-antigens, as well as antibody engineering. This innovative approach has resulted in a diversified proprietary portfolio and major alliances with leaders in the biopharmaceutical industry including Bristol-Myers Squibb, Novo Nordisk A/S, Sanofi, and a multi-products collaboration with AstraZeneca.
Headquartered in
Learn more about
Information about
ISIN code |
FR0010331421 |
|
Ticker code |
Euronext: IPH Nasdaq: IPHA |
|
LEI |
9695002Y8420ZB8HJE29 |
Disclaimer on forward-looking information and risk factors:
This press release contains certain forward-looking statements, including those within the meaning of the Private Securities Litigation Reform Act of 1995. The use of certain words, including “believe,” “potential,” “expect” and “will” and similar expressions, is intended to identify forward-looking statements. Although the company believes its expectations are based on reasonable assumptions, these forward-looking statements are subject to numerous risks and uncertainties, which could cause actual results to differ materially from those anticipated. These risks and uncertainties include, among other things, the uncertainties inherent in research and development, including related to safety, progression of and results from its ongoing and planned clinical trials and preclinical studies, review and approvals by regulatory authorities of its product candidates, the Company’s commercialization efforts, the Company’s continued ability to raise capital to fund its development and the overall impact of the COVID-19 outbreak on the global healthcare system as well as the Company’s business, financial condition and results of operations. For an additional discussion of risks and uncertainties which could cause the company's actual results, financial condition, performance or achievements to differ from those contained in the forward-looking statements, please refer to the Risk Factors (“Facteurs de Risque") section of the Universal Registration Document filed with the
This press release and the information contained herein do not constitute an offer to sell or a solicitation of an offer to buy or subscribe to shares in
View source version on businesswire.com: https://www.businesswire.com/news/home/20220214005663/en/
For additional information, please contact:
Investors
Tel.: +33 761 88 38 74
Henry.wheeler@innate-pharma.fr
Media
Tel.: +1 240 801 0076
Tracy.Rossin@innate-pharma.com
Marie Puvieux (
Tel.: +33 (0)9 81 87 46 72
innate-pharma@atcg-partners.com
Source: